Development of an Aryloxazole Derivative as a Brain-Permeable Anti-Glioblastoma Agent
- Development of an Aryloxazole Derivative as a Brain-Permeable Anti-Glioblastoma Agent
- 배애님; 김윤경; 임성수; 송지연; 신슬기; 김도희; 최민정; Changed G. Gadhe; 박아영
- aryloxazole derivative; P-glycoprotein inhibition; anti-glioblastoma agent
- Issue Date
- VOL 11-497-14
- Glioblastoma drug development has been dicult due to the extremely low blood brain barrier (BBB) penetration of conventional anti-cancer agents. P-glycoprotein, an eux membrane transporter, is responsible for the poor brain uptake of small and hydrophobic drug substances.
To develop brain-penetrable anti-tumor agents, we designed colchicine derivatives containing an aryloxazole moiety, which is known to inhibit P-glycoprotein. Among those tested, an aryloxazole derivative named KIST-G1 showed the strongest anti-glioblastoma cell proliferation activity (IC50 = 3.2 0.8 nM). Compared to colchicine, KIST-G1 showed dramatically increased BBB-permeable properties presenting 51.7 0.5 (10􀀀 6 cm/s) parallel artificial membrane permeability assay (PAMPA) permeability and 45.0 6.0% of P-gp inhibition. Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 0.1% reduced tumor area compared with phosphate buered saline (PBS)-injected control. In comparison, temozolomide, which is the most widely used drug for glioblastoma, showed only moderate eects. Our results demonstrate the eectiveness of an aryloxazole moiety in targeting brain tumors and suggest KIST-G1 as a potent anti-glioblastoma agent.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.